Eurofins Discovery

Eurofins Discovery is a global contract research organization (CRO) specializing in drug discovery services, with over 40 years of experience supporting pharmaceutical and biotech research. The company is recognized as an industry leader for offering the largest and most diverse portfolio of standard and custom in vitro safety and pharmacology assays and panels for drug screening and profiling.

The company offers a comprehensive portfolio of more than 23,000 services and products, spanning medicinal and synthetic chemistry, in vitro pharmacology, safety pharmacology, ADME-Tox, cell-based phenotypic assays, and custom protein and assay development. It supports a wide range of drug discovery targets including GPCRs, kinases, ion channels, and nuclear hormone receptors, covering programs from concept through to preclinical stages.

Eurofins Discovery is headquartered in St. Charles, Missouri, USA, and has grown through strategic acquisitions since 2012, incorporating companies such as Cerep, Panlabs, DiscoverX®, Villapharma, and Beacon Discovery. It operates as the drug discovery arm of Eurofins Scientific, an international life sciences group active in 62 countries with over 900 laboratories performing more than 450 million analytical tests annually.

As a major enabler of early-stage drug development, Eurofins Discovery is highly relevant to innovations in assay technology, AI-driven drug screening, novel target identification, and any tools or platforms that accelerate preclinical research pipelines.